Xeris Biopharma Holdings (XERS) Net Income towards Common Stockholders (2020 - 2026)

Xeris Biopharma Holdings (XERS) has 7 years of Net Income towards Common Stockholders data on file, last reported at $2.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 124.23% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (up 126.64% YoY) and the FY2025 annual result came in at $554000.0, up 101.01% from the prior year.
• Net Income towards Common Stockholders declined to $2.2 million in Q1 2026, from $11.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $11.1 million in Q4 2025 to a low of -$33.7 million in Q1 2022.
• A 5-year average of -$12.3 million and a median of -$13.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 83.12% — and 2025, when it surged 316.72%.
• Tracing XERS's Net Income towards Common Stockholders over 5 years: stood at -$12.9 million in 2022, then decreased by 3.56% to -$13.4 million in 2023, then soared by 61.81% to -$5.1 million in 2024, then surged by 316.72% to $11.1 million in 2025, then tumbled by 79.84% to $2.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $2.2 million (Q1 2026), $11.1 million (Q4 2025), and $621000.0 (Q3 2025), per Business Quant data.